The effect of common medications on the efficacy of immune checkpoint inhibitors
In this study, commonly prescribed medications did not appear to alter ICI efficacy in stage IV NSCLC. Prior associations reported in the literature may be attributable to unmeasured confounding rather than true drug-immunotherapy interactions.
Authors
- Luke M. Higgins (ORCID: https://orcid.org/0000-0002-4003-8535)
- David A. Elliott (ORCID: https://orcid.org/0009-0005-5548-5572)
- Michael D. Green (ORCID: https://orcid.org/0000-0003-4951-7118)
- Daria Brinzevich
- Garth William Strohbehn (ORCID: https://orcid.org/0000-0003-2973-3040)
- Matthew J. Schipper (ORCID: https://orcid.org/0000-0001-6728-4720)
- Alex K. Bryant (ORCID: https://orcid.org/0000-0003-0194-8381)
- Virginia Falvello
- Michael Dykstra (ORCID: https://orcid.org/0000-0003-0834-7669)
- Nithya Ramnath (ORCID: https://orcid.org/0000-0003-3641-5630)
- Sadiq Rehmani
Institutions
- University of Michigan (US)
- VA Ann Arbor Healthcare System (US)
- Michigan Medicine (US)
- VA Center for Clinical Management Research (US)
- Michigan Cancer Research Consortium (US)
- Ann Arbor VA Medical Center (US)
- Alaska Neurology Center (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-12-14
- DOI
- https://doi.org/10.1002/cncr.70222
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00